Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection.

Montalvo-Alvarez AM, Folgueira C, Carrión J, Monzote-Fidalgo L, Cañavate C, Requena JM.

J Biomed Biotechnol. 2008;2008:695432. doi: 10.1155/2008/695432.

2.

Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.

Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.

Microbes Infect. 2007 Jul;9(9):1070-7. Epub 2007 May 16.

PMID:
17644455
3.

DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.

Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C.

Vaccine. 2009 Jan 1;27(1):99-106. doi: 10.1016/j.vaccine.2008.10.013. Epub 2008 Oct 23.

PMID:
18951941
4.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.

5.

Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP.

Infect Immun. 2003 Jul;71(7):3988-94.

6.
7.
8.

TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens.

Pinheiro RO, Pinto EF, Lopes JR, Guedes HL, Fentanes RF, Rossi-Bergmann B.

Microbes Infect. 2005 Oct;7(13):1317-23. Epub 2005 Jun 13.

PMID:
16027022
9.

Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.

Vilela Mde C, Gomes DC, Marques-da-Silva Ede A, Serafim TD, Afonso LC, Rezende SA.

Acta Trop. 2007 Nov-Dec;104(2-3):133-9. Epub 2007 Aug 31.

PMID:
17919443
10.

[Monoclonal antibodies against defined Leishmania antigens protect mice against infection by different species of Leishmania].

Monjour L, Berneman A, Vouldoukis I, Domurado M, Guillemin MC, Chopin C, Alfred C, Roseto A.

C R Acad Sci III. 1985;300(9):395-8. French.

PMID:
3922585
11.

Leishmaniasis: current status of vaccine development.

Sukumaran B, Madhubala R.

Curr Mol Med. 2004 Sep;4(6):667-79. Review.

PMID:
15357215
12.
13.

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.

Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.

Exp Parasitol. 2011 Mar;127(3):627-36. doi: 10.1016/j.exppara.2010.12.007. Epub 2010 Dec 25.

PMID:
21187087
14.

Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.

Cargnelutti DE, Salomón MC, Celedon V, García Bustos MF, Morea G, Cuello-Carrión FD, Scodeller EA.

J Microbiol Immunol Infect. 2016 Feb;49(1):24-32. doi: 10.1016/j.jmii.2014.01.006. Epub 2014 Mar 21.

15.

Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes.

Colhone MC, Silva-Jardim I, Stabeli RG, Ciancaglini P.

J Microencapsul. 2015;32(2):143-50. doi: 10.3109/02652048.2014.958203. Epub 2014 Sep 29.

PMID:
25265060
16.

Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains.

Benhnini F, Chenik M, Laouini D, Louzir H, Cazenave PA, Dellagi K.

Clin Vaccine Immunol. 2009 Nov;16(11):1529-37. doi: 10.1128/CVI.00153-09. Epub 2009 Sep 2.

17.

Analysis of iron superoxide dismutase-encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection.

Campos BL, Silva TN, Ribeiro SP, Carvalho KI, Kallás EG, Laurenti MD, Passero LF.

Parasite Immunol. 2015 Aug;37(8):407-16. doi: 10.1111/pim.12206.

18.
19.

Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Salay G, Dorta ML, Santos NM, Mortara RA, Brodskyn C, Oliveira CI, Barbiéri CL, Rodrigues MM.

Clin Vaccine Immunol. 2007 Sep;14(9):1173-81. Epub 2007 Jul 11.

20.

Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.

Martins VT, Lage DP, Duarte MC, Costa LE, Chávez-Fumagalli MA, Roatt BM, Menezes-Souza D, Tavares CA, Coelho EA.

Parasite Immunol. 2016 Feb;38(2):108-17. doi: 10.1111/pim.12304.

Supplemental Content

Support Center